nach oben

Cancer and Metastasis Reviews

Erschienen in:

27.06.2020

Long non-coding RNA: A recently accentuated molecule in chemoresistance in cancer

verfasst von: Yang Peng, Dihong Tang, Meng Zhao, Hiroaki Kajiyama, Fumitaka Kikkawa, Yutaka Kondo

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Chemotherapy is one of the important and effective options for cancer treatment in the past decades. Although the response rate of initial chemotherapy is considerably high in certain types of cancers, such as ovarian cancer and lung cancer, the patients frequently suffer from chemoresistance and recurrence of disease. Recent genome-wide studies have shown that the large number of long non-coding RNAs (lncRNAs) are transcribed from the human genome and involved in many biological processes including carcinogenesis. They aberrantly regulate variety of cell functions, such as cell cycle, apoptosis, autophagy, and metabolisms, which are associated with chemosensitivity. Therefore, understanding the biological and clinical impacts of lncRNAs on tumor behavior and its potential as a predictive biomarker for chemotherapy effectiveness is highly desired. In this review, we classify the major mechanisms of lncRNA-related chemoresistance and provide theoretical evidences for targeting lncRNAs in certain types of cancers that may open up new therapeutic paradigm for cancer treatment.

Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019). Cancer treatment and survivorship statistics, 2019. CA: a cancer journal for clinicians, 69, 363–385.

W.O. Rebecca, M.A. Richard, Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus, The Cochrane database of systematic reviews, (2003) Cd002092.

E. Wakeam, S.A. Acuna, N.B. Leighl, M.E. Giuliani, S.R.G. Finlayson, T.K. Varghese, G.E. Darling, Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: a propensity-matched analysis of survival, Lung cancer (Amsterdam, Netherlands), 109 (2017) 78-88.

M.L. Ashdown, A.P. Robinson, S.L. Yatomi-Clarke, M.L. Ashdown, A. Allison, D. Abbott, S.N. Markovic, B.J. Coventry, Chemotherapy for late-stage cancer patients: meta-analysis of complete response rates, F1000Research, 4 (2015) 232.

Shewach, D. S., & Kuchta, R. D. (2009). Introduction to cancer chemotherapeutics. Chemical reviews, 109, 2859–2861.PubMedPubMedCentral

Falzone, L., Salomone, S., & Libra, M. (2018). Evolution of cancer pharmacological treatments at the turn of the third millennium. Frontiers in pharmacology, 9, 1300.PubMedPubMedCentral

Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014). Drug resistance in cancer: an overview. Cancers, 6, 1769–1792.PubMedPubMedCentral

Swain, S. M. (2011). Chemotherapy: updates and new perspectives. The oncologist, 16(Suppl 1), 30–39.PubMed

Colombo, N., Lorusso, D., & Scollo, P. (2017). Impact of recurrence of ovarian cancer on quality of life and outlook for the future. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 27, 1134–1140.

10.

Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017). The different mechanisms of cancer drug resistance: a brief review. Advanced pharmaceutical bulletin, 7, 339–348.PubMedPubMedCentral

11.

Luqmani, Y. A. (2005). Mechanisms of drug resistance in cancer chemotherapy. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 14(Suppl 1), 35–48.

12.

T. Nunes, D. Hamdan, C. Leboeuf, M. El Bouchtaoui, G. Gapihan, T.T. Nguyen, S. Meles, E. Angeli, P. Ratajczak, H. Lu, M. Di Benedetto, G. Bousquet, A. Janin, Targeting cancer stem cells to overcome chemoresistance, International journal of molecular sciences, 19 (2018).

13.

Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., Han, W., Lou, F., Yang, J., Zhang, Q., Wang, X., He, C., & Pan, H. (2013). Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell death & disease, 4, e838.

14.

Kondo, Y., Shinjo, K., & Katsushima, K. (2017). Long non-coding RNAs as an epigenetic regulator in human cancers. Cancer science, 108, 1927–1933.PubMedPubMedCentral

15.

Schmitt, A. M., & Chang, H. Y. (2016). Long Noncoding RNAs in Cancer Pathways. Cancer cell, 29, 452–463.PubMedPubMedCentral

16.

Guttman, M., Donaghey, J., Carey, B. W., Garber, M., Grenier, J. K., Munson, G., Young, G., Lucas, A. B., Ach, R., Bruhn, L., Yang, X., Amit, I., Meissner, A., Regev, A., Rinn, J. L., Root, D. E., & Lander, E. S. (2011). lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature, 477, 295–300.PubMedPubMedCentral

17.

Liu, K., Gao, L., Ma, X., Huang, J. J., Chen, J., Zeng, L., Ashby Jr., C. R., Zou, C., & Chen, Z. S. (2020). Long non-coding RNAs regulate drug resistance in cancer. Molecular cancer, 19, 54.PubMedPubMedCentral

18.

Wang, J., & Lindahl, T. (2016). Maintenance of genome stability. Genomics, proteomics & bioinformatics, 14, 119–121.

19.

Tubbs, A., & Nussenzweig, A. (2017). Endogenous DNA damage as a source of genomic instability in cancer. Cell, 168, 644–656.PubMedPubMedCentral

20.

Nagel, Z. D., Kitange, G. J., Gupta, S. K., Joughin, B. A., Chaim, I. A., Mazzucato, P., Lauffenburger, D. A., Sarkaria, J. N., & Samson, L. D. (2017). DNA repair capacity in multiple pathways predicts chemoresistance in glioblastoma multiforme. Cancer research, 77, 198–206.PubMed

21.

Brandsma, I., & Gent, D. C. (2012). Pathway choice in DNA double strand break repair: observations of a balancing act. Genome integrity, 3, 9.PubMedPubMedCentral

22.

Hosoya, N., & Miyagawa, K. (2014). Targeting DNA damage response in cancer therapy. Cancer science, 105, 370–388.PubMedPubMedCentral

23.

Zhang, Y., He, Q., Hu, Z., Feng, Y., Fan, L., Tang, Z., Yuan, J., Shan, W., Li, C., Hu, X., Tanyi, J. L., Fan, Y., Huang, Q., Montone, K., Dang, C. V., & Zhang, L. (2016). Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nature structural & molecular biology, 23, 522–530.

24.

X. Wang, H. Liu, L. Shi, X. Yu, Y. Gu, X. Sun, LINP1 facilitates DNA damage repair through non-homologous end joining (NHEJ) pathway and subsequently decreases the sensitivity of cervical cancer cells to ionizing radiation, Cell cycle (Georgetown, Tex.), 17 (2018) 439-447.

25.

Wu, P., Cai, J., Chen, Q., Han, B., Meng, X., Li, Y., Li, Z., Wang, R., Lin, L., Duan, C., Kang, C., & Jiang, C. (2019). Lnc-TALC promotes O(6)-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nature communications, 10, 2045.PubMedPubMedCentral

26.

C.C. Chen, C.Y. Chen, S.H. Wang, C.T. Yeh, S.C. Su, S.H. Ueng, W.Y. Chuang, C. Hsueh, T.H. Wang, Melatonin sensitizes hepatocellular carcinoma cells to chemotherapy through long non-coding RNA RAD51-AS1-mediated suppression of DNA repair, Cancers, 10 (2018).

27.

Sharma, V., Khurana, S., Kubben, N., Abdelmohsen, K., Oberdoerffer, P., Gorospe, M., & Misteli, T. (2015). A BRCA1-interacting lncRNA regulates homologous recombination. EMBO reports, 16, 1520–1534.PubMedPubMedCentral

28.

Liu, Z., Sun, M., Lu, K., Liu, J., Zhang, M., Wu, W., De, W., Wang, Z., & Wang, R. (2013). The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PloS one, 8, e77293.PubMedPubMedCentral

29.

Wang, H., Fang, L., Jiang, J., Kuang, Y., Wang, B., Shang, X., Han, P., Li, Y., Liu, M., Zhang, Z., & Li, P. (2018). The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Cell death & disease, 9, 1103.

30.

Gao, H., Song, X., Kang, T., Yan, B., Feng, L., Gao, L., Ai, L., Liu, X., Yu, J., & Li, H. (2017). Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. OncoTargets and therapy, 10, 205–216.PubMedPubMedCentral

31.

Modok, S., Mellor, H. R., & Callaghan, R. (2006). Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Current opinion in pharmacology, 6, 350–354.PubMed

32.

Sharom, F. J. (2008). ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics, 9, 105–127.PubMed

33.

Abbasifarid, E., Sajjadi-Jazi, S. M., Beheshtian, M., Samimi, H., Larijani, B., & Haghpanah, V. (2019). The role of ATP-binding cassette transporters in the chemoresistance of anaplastic thyroid cancer: a systematic review. Endocrinology, 160, 2015–2023.PubMed

34.

Schondorf, T., Neumann, R., Benz, C., Becker, M., Riffelmann, M., Gohring, U. J., Sartorius, J., von Konig, C. H., Breidenbach, M., Valter, M. M., Hoopmann, M., Di Nicolantonio, F., & Kurbacher, C. M. (2003). Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 161, 111–116.PubMed

35.

E.L. Christie, S. Pattnaik, J. Beach, A. Copeland, N. Rashoo, S. Fereday, J. Hendley, K. Alsop, S.L. Brady, G. Lamb, A. Pandey, A. deFazio, H. Thorne, A. Bild, D.D.L. Bowtell, Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer, Nature communications, 10 (2019) 1295.

36.

Gao, H., Hao, G., Sun, Y., Li, L., & Wang, Y. (2018). Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process. OncoTargets and therapy, 11, 8001–8012.PubMedPubMedCentral

37.

Zhu, Q. N., Wang, G., Guo, Y., Peng, Y., Zhang, R., Deng, J. L., Li, Z. X., & Zhu, Y. S. (2017). LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget, 8, 91990–92003.PubMedPubMedCentral

38.

Tsang, W. P., & Kwok, T. T. (2007). Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene, 26, 4877–4881.PubMed

39.

Jiang, P., Wang, P., Sun, X., Yuan, Z., Zhan, R., Ma, X., & Li, W. (2016). Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy. OncoTargets and therapy, 9, 3501–3509.PubMedPubMedCentral

40.

Shi, C., & Wang, M. (2018). LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1. Medical science monitor : international medical journal of experimental and clinical research, 24, 8831–8839.

41.

Wang, J., Ye, C., Liu, J., & Hu, Y. (2018). UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. Biochemical and biophysical research communications, 501, 1034–1040.PubMed

42.

B. Ding, W. Lou, L. Xu, W. Fan, Non-coding RNA in drug resistance of hepatocellular carcinoma, Bioscience reports, 38 (2018).

43.

Huang, H., Chen, J., Ding, C. M., Jin, X., Jia, Z. M., & Peng, J. (2018). LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363. Journal of cellular and molecular medicine, 22, 3238–3245.PubMedPubMedCentral

44.

Takahashi, K., Yan, I. K., Wood, J., Haga, H., & Patel, T. (2014). Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Molecular cancer research : MCR, 12, 1377–1387.PubMed

45.

Z. Fang, W. Chen, Z. Yuan, X. Liu, H. Jiang, LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 101 (2018) 536-542.

46.

X. Wu, Y. Zheng, B. Han, X. Dong, Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 99 (2018) 832-838.

47.

Abraham, R. T. (2001). Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes & development, 15, 2177–2196.

48.

Bartek, J., & Lukas, J. (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer cell, 3, 421–429.PubMed

49.

Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008). DNA repair pathways as targets for cancer therapy. Nature reviews. Cancer, 8, 193–204.PubMed

50.

Adriaens, C., Standaert, L., Barra, J., Latil, M., Verfaillie, A., Kalev, P., Boeckx, B., Wijnhoven, P. W., Radaelli, E., Vermi, W., Leucci, E., Lapouge, G., Beck, B., van den Oord, J., Nakagawa, S., Hirose, T., Sablina, A. A., Lambrechts, D., Aerts, S., Blanpain, C., & Marine, J. C. (2016). p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity. Nature medicine, 22, 861–868.PubMed

51.

Shin, V. Y., Chen, J., Cheuk, I. W., Siu, M. T., Ho, C. W., Wang, X., Jin, H., & Kwong, A. (2019). Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell death & disease, 10, 270.

52.

Lu, Y., Hu, Z., Mangala, L. S., Stine, Z. E., Hu, X., Jiang, D., Xiang, Y., Zhang, Y., Pradeep, S., Rodriguez-Aguayo, C., Lopez-Berestein, G., DeMarzo, A. M., Sood, A. K., Zhang, L., & Dang, C. V. (2018). MYC Targeted long noncoding RNA DANCR promotes cancer in part by reducing p21 Levels. Cancer research, 78, 64–74.PubMed

53.

Lu, C., Wei, Y., Wang, X., Zhang, Z., Yin, J., Li, W., Chen, L., Lyu, X., Shi, Z., Yan, W., & You, Y. (2020). DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Molecular cancer, 19, 28.PubMedPubMedCentral

54.

Shang, J., Xu, Y. D., Zhang, Y. Y., & Li, M. (2019). Long noncoding RNA OR3A4 promotes cisplatin resistance of non-small cell lung cancer by upregulating CDK1. European review for medical and pharmacological sciences, 23, 4220–4225.PubMed

55.

Jiang, H., Xiong, W., Chen, L., Lv, Z., Yang, C., & Li, Y. (2019). Knockdown of the long noncoding RNA HOTTIP inhibits cell proliferation and enhances cell sensitivity to cisplatin by suppressing the Wnt/beta-catenin pathway in prostate cancer. Journal of cellular biochemistry, 120, 8965–8974.PubMed

56.

Sun, W., Xu, X., Jiang, Y., Jin, X., Zhou, P., Liu, Y., Guo, Y., Ma, D., Zuo, W., Huang, S., He, X., & Shao, Z. (2019). Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance. International journal of cancer, 145, 842–856.PubMed

57.

Zuo, W., Zhang, W., Xu, F., Zhou, J., & Bai, W. (2019). Long non-coding RNA LINC00485 acts as a microRNA-195 sponge to regulate the chemotherapy sensitivity of lung adenocarcinoma cells to cisplatin by regulating CHEK1. Cancer cell international, 19, 240.PubMedPubMedCentral

58.

Liu, M., Zhang, H., Li, Y., Wang, R., Li, Y., Zhang, H., Ren, D., Liu, H., Kang, C., & Chen, J. (2018). HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer. Cancer science, 109, 2717–2733.PubMedPubMedCentral

59.

G. Mor, M.K. Montagna, A.B. Alvero, Modulation of apoptosis to reverse chemoresistance, Methods in molecular biology (Clifton, N.J.), 414 (2008) 1-12.

60.

Fraser, M., Leung, B., Jahani-Asl, A., Yan, X., Thompson, W. E., & Tsang, B. K. (2003). Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reproductive biology and endocrinology : RB&E, 1, 66.

61.

Fridman, J. S., & Lowe, S. W. (2003). Control of apoptosis by p53. Oncogene, 22, 9030–9040.PubMed

62.

Wong, R. S. (2011). Apoptosis in cancer: from pathogenesis to treatment. Journal of experimental & clinical cancer research : CR, 30, 87.

63.

Han, J., Han, B., Wu, X., Hao, J., Dong, X., Shen, Q., & Pang, H. (2018). Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicology and applied pharmacology, 359, 55–61.PubMed

64.

Si, X., Zang, R., Zhang, E., Liu, Y., Shi, X., Zhang, E., Shao, L., Li, A., Yang, N., Han, X., Pan, B., Zhang, Z., Sun, L., & Sun, Y. (2016). LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget, 7, 81452–81462.PubMedPubMedCentral

65.

Wang, F., Zhou, J., Xie, X., Hu, J., Chen, L., Hu, Q., Guo, H., & Yu, C. (2015). Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma.

66.

Pan, J., Li, X., Wu, W., Xue, M., Hou, H., Zhai, W., & Chen, W. (2016). Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer letters, 382, 64–76.PubMed

67.

Chen, X., Liu, M., Meng, F., Sun, B., Jin, X., & Jia, C. (2019). The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer. Journal of cellular biochemistry, 120, 243–252.PubMed

68.

Du, P., Hu, C., Qin, Y., Zhao, J., Patel, R., Fu, Y., Zhu, M., Zhang, W., & Huang, G. (2019). LncRNA PVT1 Mediates Antiapoptosis and 5-Fluorouracil Resistance via Increasing Bcl2 Expression in Gastric Cancer. Journal of oncology, 2019, 9325407.PubMedPubMedCentral

69.

Yue, B., Cai, D., Liu, C., Fang, C., & Yan, D. (2016). Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Molecular therapy : the journal of the American Society of Gene Therapy, 24, 2064–2077.

70.

Nieto, M. A., Huang, R. Y., Jackson, R. A., & Thiery, J. P. (2016). EMT: 2016. Cell, 166, 21–45.

71.

van Staalduinen, J., Baker, D., Ten Dijke, P., & van Dam, H. (2018). Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene, 37, 6195–6211.PubMed

72.

Zhang, H. Y., Liang, F., Zhang, J. W., Wang, F., Wang, L., & Kang, X. G. (2017). Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205. Cancer chemotherapy and pharmacology, 79, 327–337.PubMed

73.

Chen, Y. M., Liu, Y., Wei, H. Y., Lv, K. Z., & Fu, P. (2016). Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 37, 10861–10870.

74.

An, J., Lv, W., & Zhang, Y. (2017). LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. OncoTargets and therapy, 10, 5377–5390.PubMedPubMedCentral

75.

Li, P., Zhang, X., Wang, H., Wang, L., Liu, T., Du, L., Yang, Y., & Wang, C. (2017). MALAT1 Is Associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Molecular cancer therapeutics, 16, 739–751.PubMed

76.

Jia, J., Zhan, D., Li, J., Li, Z., Li, H., & Qian, J. (2019). The contrary functions of lncRNA HOTAIR/miR-17-5p/PTEN axis and Shenqifuzheng injection on chemosensitivity of gastric cancer cells. Journal of cellular and molecular medicine, 23, 656–669.PubMed

77.

Glick, D., Barth, S., & Macleod, K. F. (2010). Autophagy: cellular and molecular mechanisms. The Journal of pathology, 221, 3–12.PubMedPubMedCentral

78.

Colhado Rodrigues, B. L., Lallo, M. A., & Perez, E. C. (2020). The controversial role of autophagy in tumor development: a systematic review. Immunological investigations, 49, 386–396.PubMed

79.

Kim, J., Kundu, M., Viollet, B., & Guan, K. L. (2011). AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nature cell biology, 13, 132–141.PubMedPubMedCentral

80.

Mizushima, N. (2019). The ATG conjugation systems in autophagy. Current opinion in cell biology, 63, 1–10.PubMed

81.

Zhang, W., Liu, Y., Fu, Y., Han, W., Xu, H., Wen, L., Deng, Y., & Liu, K. (2020). Long non-coding RNA LINC00160 functions as a decoy of microRNA-132 to mediate autophagy and drug resistance in hepatocellular carcinoma via inhibition of PIK3R3. Cancer letters, 478, 22–33.PubMed

82.

Cai, Q., Wang, S., Jin, L., Weng, M., Zhou, D., Wang, J., Tang, Z., & Quan, Z. (2019). Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy. Molecular cancer, 18, 82.PubMedPubMedCentral

83.

Wang, M., Han, D., Yuan, Z., Hu, H., Zhao, Z., Yang, R., Jin, Y., Zou, C., Chen, Y., Wang, G., Gao, X., & Wang, X. (2018). Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell death & disease, 9, 1149.

84.

YiRen, H., YingCong, Y., Sunwu, Y., Keqin, L., Xiaochun, T., Senrui, C., Ende, C., XiZhou, L., & Yanfan, C. (2017). Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Molecular cancer, 16, 174.PubMedPubMedCentral

85.

Xiong, H., Ni, Z., He, J., Jiang, S., Li, X., He, J., Gong, W., Zheng, L., Chen, S., Li, B., Zhang, N., Lyu, X., Huang, G., Chen, B., Zhang, Y., & He, F. (2017). LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene, 36, 3528–3540.PubMed

86.

Xu, S., Wang, P., Zhang, J., Wu, H., Sui, S., Zhang, J., Wang, Q., Qiao, K., Yang, W., Xu, H., & Pang, D. (2019). Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer. Molecular cancer, 18, 89.PubMedPubMedCentral

87.

Quintana, E., Shackleton, M., Foster, H. R., Fullen, D. R., Sabel, M. S., Johnson, T. M., & Morrison, S. J. (2010). Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer cell, 18, 510–523.PubMedPubMedCentral

88.

Kim, Y., Joo, K. M., Jin, J., & Nam, D. H. (2009). Cancer stem cells and their mechanism of chemo-radiation resistance. International journal of stem cells, 2, 109–114.PubMedPubMedCentral

89.

Ntziachristos, P., Abdel-Wahab, O., & Aifantis, I. (2016). Emerging concepts of epigenetic dysregulation in hematological malignancies. Nature immunology, 17, 1016–1024.PubMedPubMedCentral

90.

Lohitesh, K., Chowdhury, R., & Mukherjee, S. (2018). Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer cell international, 18, 44.PubMedPubMedCentral

91.

Wang, H., Li, W., Guo, R., Sun, J., Cui, J., Wang, G., Hoffman, A. R., & Hu, J. F. (2014). An intragenic long noncoding RNA interacts epigenetically with the RUNX1 promoter and enhancer chromatin DNA in hematopoietic malignancies. International journal of cancer, 135, 2783–2794.PubMed

92.

Chen, X., Xie, R., Gu, P., Huang, M., Han, J., Dong, W., Xie, W., Wang, B., He, W., Zhong, G., Chen, Z., Huang, J., & Lin, T. (2019). Long noncoding RNA LBCS inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2. Clinical cancer research : an official journal of the American Association for Cancer Research, 25, 1389–1403.

93.

He, W., Liang, B., Wang, C., Li, S., Zhao, Y., Huang, Q., Liu, Z., Yao, Z., Wu, Q., Liao, W., Zhang, S., Liu, Y., Xiang, Y., Liu, J., & Shi, M. (2019). MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene, 38, 4637–4654.PubMedPubMedCentral

94.

Katsushima, K., Natsume, A., Ohka, F., Shinjo, K., Hatanaka, A., Ichimura, N., Sato, S., Takahashi, S., Kimura, H., Totoki, Y., Shibata, T., Naito, M., Kim, H. J., Miyata, K., Kataoka, K., & Kondo, Y. (2016). Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nature communications, 7, 13616.PubMedPubMedCentral

Titel: Long non-coding RNA: A recently accentuated molecule in chemoresistance in cancer
verfasst von: Yang Peng
Dihong Tang
Meng Zhao
Hiroaki Kajiyama
Fumitaka Kikkawa
Yutaka Kondo
Publikationsdatum: 27.06.2020
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2020
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-020-09910-w

Springer Medizin

Long non-coding RNA: A recently accentuated molecule in chemoresistance in cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

The role of fibroblast activation protein in health and malignancy

CDK7 inhibitors as anticancer drugs

BRMS1: a multifunctional signaling molecule in metastasis

KISS1 in metastatic cancer research and treatment: potential and paradoxes

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy

Brain tumor vessels—a barrier for drug delivery

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie